Summary
CME Group Inc. (CME) announced a significant leadership transition and changes to its corporate governance structure via an 8-K filing on February 6, 2020. Bryan T. Durkin will step down as President in May 2020, transitioning to a special advisor role reporting to the CEO. This move signals a shift in executive responsibilities and is accompanied by an amendment to the company's bylaws. The company's Board of Directors amended its bylaws to modify the nomination process for Class B Directors, effective February 5, 2020. Key changes include the elimination of Class B Nominating Committees starting from the 2021 annual meeting, with eligible nominees now to be selected by the Board's Nominating and Governance Committee alongside existing write-in requirements. Additionally, the Nominating and Governance Committees have been formally combined into a single committee. These governance adjustments are designed to streamline the director nomination process.
Key Highlights
- 1Bryan T. Durkin to step down as President in May 2020.
- 2Mr. Durkin will assume a new role as a special advisor to the CEO.
- 3Bylaws amended to change the nomination process for Class B Directors, effective February 5, 2020.
- 4Class B Nominating Committees will be eliminated starting with the 2021 annual meeting.
- 5Nominees for Class B Directors will be selected by the Board's Nominating and Governance Committee and eligible write-in candidates from 2021 onwards.
- 6The Nominating and Governance Committees of the Board have been formally combined into one committee.
- 7The company issued a press release on February 6, 2020, detailing Mr. Durkin's transition.